Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 May 1;214(5):1547–1555. doi: 10.1084/jem.20161451

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2017 Rodero et al.

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).

PMC Copyright notice

Figure 4. — Disease associations of serum IFNα in SLE patients. (A–D) Higher serum IFNα levels associate with higher SLEDAI (P < 0.001; A), ESR (P < 0.01; B), lower CH50 activity (P < 0.001; C), and number of specific autoantibodies against ribonucleoproteins (anti-Ro, La, Sm, RNP; P < 0.0001; D). IFNα <10 fg/ml: n = 25; IFNα = 10–300 fg/ml: n = 14; IFNα >300 fg/ml: n = 8; one-way ANOVA (Kruskal–Wallis) p-values are reported. (E) Profile of autoantibodies directed against ribonucleoproteins in patients with low, intermediate, and high IFN levels. Green, <25 U/ml; yellow, 25–50 U/ml; orange, 50–100 U/ml; red, >100 U/ml. A positive result is >25 U/ml. The total number of autoantibodies against ribonucleoproteins (anti-Ro, La, Sm, RNP) is significantly increased in patients with the highest levels of serum IFNα (two-way ANOVA, P < 0.0001). *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001; n.s., not significant; horizontal lines indicate median.